The Phase II study of Gemtuzumab Ozogamicin (Mylotarg) combined with standard dose cytarabine targets relapsed acute myeloid leukemia (AML) patients, specifically those with CD33-positive tumors. Given the high unmet medical need in relapsed AML, successful outcomes could position this combination therapy as a competitive treatment option in a market characterized by limited effective therapies. The collaboration with SWOG Cancer Research Network and the National Cancer Institute (NCI) enhances credibility and may facilitate further development or regulatory pathways. The market for AML therapies is growing, driven by increasing incidence rates and advancements in personalized medicine, suggesting potential for significant commercial returns if the trial demonstrates efficacy and safety.